New Zealand details pilots of key diagnostic programmes
This article was originally published in Clinica
New Zealand's health ministry has published the details of pilots it has conducted over the last year for a series of in vitro diagnostics, imaging and other clinical assessment programmes.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.